Hannes Hagström1,2, Per Stål1,3, Rolf Hultcrantz1,3, Kerstin Brismar4, Ishrath Ansurudeen4. 1. a Unit of Hepatology , Centre for Digestive Diseases, Karolinska University Hospital , Stockholm , Sweden. 2. b Department of Medicine, Clinical Epidemiology Unit , Karolinska Institutet , Stockholm , Sweden. 3. c Department of Medicine , Karolinska Institutet , Stockholm , Sweden. 4. d Department of Molecular Medicine and Surgery , Rolf Luft Research Centre for Diabetes and Endocrinology, Karolinska Institutet , Stockholm , Sweden.
Abstract
BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease globally. Advanced fibrosis (stage 3-4) is the most robust marker for future mortality, but diagnosis requires liver biopsy. Current non-invasive scoring systems aimed to identify advanced fibrosis are imperfect. Insulin-like growth factor I (IGF-I) and its binding protein IGFBP-1 are liver derived proteins, that are involved in various liver disorders. The aim of this study was to examine the possible association between advanced fibrosis and IGF-I and IGFBP-1 in NAFLD. METHODS: Fasting blood samples were obtained from 52 patients diagnosed with NAFLD by liver biopsy. Total IGF-I and IGFBP-1 concentrations were determined in serum by in-house radio-immuno-assays. IGF-I levels were age-standardized (IGF-SD). A logistic regression model was used to investigate the association of IGF-SD and IGFBP-1 with advanced fibrosis (stage 3-4). RESULTS: Patients with advanced fibrosis (stage 3-4 vs. 0-2) had lower IGF-SD (-1.17 vs. 0.11, p = .01) and higher mean levels of IGFBP-1 (29.9 vs. 18.8 µg/l, p = .02). IGFBP-1 was associated with presence of advanced fibrosis (OR 1.04 per unit increase, 95%CI 1.0-1.07, p = .05), while IGF-1 was negatively associated with advanced fibrosis (OR 0.63 per standard deviation, 95%CI 0.44-0.92, p = .02). CONCLUSIONS: This pilot study suggests an association between serum IGFBP-1 and IGF-I levels with advanced fibrosis in NAFLD patients. IGFBP1 and IGF-1 could be of interest as future biomarkers. Similar studies in larger cohorts are needed.
BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease globally. Advanced fibrosis (stage 3-4) is the most robust marker for future mortality, but diagnosis requires liver biopsy. Current non-invasive scoring systems aimed to identify advanced fibrosis are imperfect. Insulin-like growth factor I (IGF-I) and its binding protein IGFBP-1 are liver derived proteins, that are involved in various liver disorders. The aim of this study was to examine the possible association between advanced fibrosis and IGF-I and IGFBP-1 in NAFLD. METHODS: Fasting blood samples were obtained from 52 patients diagnosed with NAFLD by liver biopsy. Total IGF-I and IGFBP-1 concentrations were determined in serum by in-house radio-immuno-assays. IGF-I levels were age-standardized (IGF-SD). A logistic regression model was used to investigate the association of IGF-SD and IGFBP-1 with advanced fibrosis (stage 3-4). RESULTS:Patients with advanced fibrosis (stage 3-4 vs. 0-2) had lower IGF-SD (-1.17 vs. 0.11, p = .01) and higher mean levels of IGFBP-1 (29.9 vs. 18.8 µg/l, p = .02). IGFBP-1 was associated with presence of advanced fibrosis (OR 1.04 per unit increase, 95%CI 1.0-1.07, p = .05), while IGF-1 was negatively associated with advanced fibrosis (OR 0.63 per standard deviation, 95%CI 0.44-0.92, p = .02). CONCLUSIONS: This pilot study suggests an association between serum IGFBP-1 and IGF-I levels with advanced fibrosis in NAFLD patients. IGFBP1 and IGF-1 could be of interest as future biomarkers. Similar studies in larger cohorts are needed.
Authors: Christoffer A Hagemann; Christian Legart; Mathias B Møllerhøj; Martin R Madsen; Henrik H Hansen; Merete J Kønig; Frederik Helgstrand; Flemming P Hjørne; Anders Toxværd; Jill L Langhoff; Urd L Kielgast; Lise L Gluud; Helene Ægidius; Kristoffer T G Rigbolt; Tina Vilsbøll; Jacob Jelsing; Filip K Knop Journal: PLoS One Date: 2022-10-19 Impact factor: 3.752
Authors: Naeimeh Atabaki-Pasdar; Mattias Ohlsson; Ana Viñuela; Francesca Frau; Hugo Pomares-Millan; Mark Haid; Angus G Jones; E Louise Thomas; Robert W Koivula; Azra Kurbasic; Pascal M Mutie; Hugo Fitipaldi; Juan Fernandez; Adem Y Dawed; Giuseppe N Giordano; Ian M Forgie; Timothy J McDonald; Femke Rutters; Henna Cederberg; Elizaveta Chabanova; Matilda Dale; Federico De Masi; Cecilia Engel Thomas; Kristine H Allin; Tue H Hansen; Alison Heggie; Mun-Gwan Hong; Petra J M Elders; Gwen Kennedy; Tarja Kokkola; Helle Krogh Pedersen; Anubha Mahajan; Donna McEvoy; Francois Pattou; Violeta Raverdy; Ragna S Häussler; Sapna Sharma; Henrik S Thomsen; Jagadish Vangipurapu; Henrik Vestergaard; Leen M 't Hart; Jerzy Adamski; Petra B Musholt; Soren Brage; Søren Brunak; Emmanouil Dermitzakis; Gary Frost; Torben Hansen; Markku Laakso; Oluf Pedersen; Martin Ridderstråle; Hartmut Ruetten; Andrew T Hattersley; Mark Walker; Joline W J Beulens; Andrea Mari; Jochen M Schwenk; Ramneek Gupta; Mark I McCarthy; Ewan R Pearson; Jimmy D Bell; Imre Pavo; Paul W Franks Journal: PLoS Med Date: 2020-06-19 Impact factor: 11.069